Boostrix Adverse Reactions

Clinical Trial Data: The safety profile as follows is based on data from clinical trials where Boostrix was administered to 839 children (from 4 to 9 years of age) and 1931 adults, adolescents and children (above 10 years of age).
Adverse reactions reported are listed according to the following frequency: Very common ≥1/10; Common ≥1/100 and <1/10; Uncommon ≥1/1000 and <1/100; Rare ≥1/10,000 and <1/1000; Very rare <1/10,000.
Children from 4 to 9 years of age: Infections and infestations: Uncommon: upper respiratory tract infection.
Metabolism and nutrition disorders: Common: anorexia.
Psychiatric disorders: Very common: irritability.
Nervous system disorders: Very common: somnolence. Common: headache. Uncommon: disturbances in attention.
Eye disorders: Uncommon: conjunctivitis.
Gastrointestinal disorders: Common: diarrhoea, vomiting, gastrointestinal disorders.
Skin and subcutaneous tissue disorders: Uncommon: rash.
General disorders and administration site conditions: Very common: injection site reactions (including pain, redness and swelling), fatigue. Common: fever ≥37.5°C (including fever >39°C). Uncommon: other injection site reactions (such as induration), pain.
Adults, adolescents and children from the age of 10 years onwards: Infections and infestations: Uncommon: upper respiratory tract infection, pharyngitis.
Blood and lymphatic system disorders: Uncommon: lymphadenopathy.
Nervous system disorders: Very common: headache. Common: dizziness. Uncommon: syncope.
Respiratory, thoracic and mediastinal disorders: Uncommon: cough.
Gastrointestinal disorders: Common: nausea, gastrointestinal disorders. Uncommon: diarrhoea, vomiting.
Skin and subcutaneous tissue disorders: Uncommon: hyperhidrosis, pruritus, rash.
Musculoskeletal and connective tissue disorders: Uncommon: arthralgia, myalgia, joint stiffness, musculoskeletal stiffness.
General disorders and administration site conditions: Very common: injection site reactions (including pain, redness and swelling), fatigue, malaise. Common: fever ≥37.5°C, injection site reactions (such as injection site mass and injection site abscess sterile). Uncommon: fever >39°C, influenza-like illness, pain.
Reactogenicity after repeat dose of Boostrix: Data on 146 subjects suggest a small increase in local reactogenicity (pain, redness, swelling) with repeated vaccination according to a 0, 1, 6 months schedule in adults (>40 years of age).
Subjects fully primed with 4 doses of DTPw followed by a Boostrix dose around 10 years of age show an increase of local reactogenicity after an additional Boostrix dose administered 10 years later.
Post-Marketing Data: Blood and lymphatic system disorders: Rare: angioedema.
Immune system disorders: Very rare: allergic reactions, including anaphylactic and anaphylactoid reactions.
Nervous system disorders: Rare: convulsions (with or without fever).
Skin and subcutaneous tissue disorders: Rare: urticaria.
General disorders and administration site conditions: Rare: extensive swelling of the vaccinated limb, asthenia.